1. Home
  2. Products
  3. Customized ADCs
  4. ERBB2
  5. Anti-ERBB2 (Trastuzumab)-AO-Mc-PEG8-Dol10 (Glyco Dol10) ADC

Anti-ERBB2 (Trastuzumab)-AO-Mc-PEG8-Dol10 (Glyco Dol10) ADC (CAT#: ADC-W-390)

This ADC product is comprised of an anti-ERBB2 monoclonal antibody conjugated via a AO-Mc-PEG8 linker to aDol10 (Thiol Dol10). The Dol10 (Thiol Dol10) is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • ERBB2
  • Alternative Names
  • ERBB2; erb-b2 receptor tyrosine kinase 2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 1
  • Target Entrez Gene ID
  • 2064
  • Overview
  • This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
  • Overview
  • Humanized Anti-ERBB2 Antibody, Trastuzumab
  • Generic name
  • Trastuzumab
  • Species Reactivity
  • Human
  • Name
  • AO-Mc-PEG8
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • Dol10 (Thiol Dol10)

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-390. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Payload
CAT# Product Name Linker Payload
ADC-W-2595 Anti-ERBB2 (Trastuzumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-1112 Anti-ERBB2 (Pertuzumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-116 Anti-ERBB2 (Trastuzumab)-Gly5-modified DM1 ADC  C-terminal GS (glycine-serine) linker Gly5-modified DM1 (Gly5-modified N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-514 Anti-ERBB2 (Trastuzumab)-VC-DUBA ADC VC (valine-citrulline) seco-DUBA (DUocarmycin hydroxyBenzamide Azaindole)
ADC-W-572 Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-389 Anti-ERBB2 (Trastuzumab)-Mc-PEG8-Dol10 (Thiol Dol10) ADC MC-PEG8 Dol10 (Thiol Dol10)

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.